6533b853fe1ef96bd12ac19a

RESEARCH PRODUCT

Vascular endothelial growth factor gene polymorphisms in ovarian cancer

Lukas A. HeflerFalk ThielNicole ConcinRobert ZeillingerAlexander ReinthallerBerno TannerStephan PolterauerChristoph GrimmAlexander MusteaGeorg Heinze

subject

Vascular Endothelial Growth Factor AGenotypeAngiogenesisVEGF receptorsRegulatorVascular permeabilityLinkage Disequilibriumchemistry.chemical_compoundHumansMedicineGeneAgedNeoplasm StagingOvarian NeoplasmsPolymorphism GeneticNeovascularization Pathologicbiologybusiness.industryHaplotypeObstetrics and GynecologyMiddle AgedPrognosismedicine.diseaseVascular endothelial growth factorOncologychemistryCancer researchbiology.proteinFemalebusinessOvarian cancer

description

Abstract Background. Polymorphisms within the vascular endothelial growth factor (VEGF) gene, the most important regulator of angiogenesis and vascular permeability, were shown to be independently associated with an impaired prognosis in various malignancies. No data have been reported in ovarian cancer. Methods. In the present multi-center study, we examined three common polymorphisms within the VEGF gene ( VEGF +405G/C, VEGF −460C/T, and VEGF +936C/T) in 553 Caucasian patients with ovarian cancer using pyrosequencing. Results. The three investigated polymorphisms did not correlate with any of the investigated clinico-pathological parameters. In univariate and multivariate models, only FIGO stage and patient's age at diagnosis, but not any polymorphism or any haplotype were correlated with patients' overall survival. Conclusions. In our large multi-center study, the investigated VEGF gene polymorphisms were not associated with prognosis in patients with ovarian cancer.

yearjournalcountryeditionlanguage
2007-05-01Gynecologic Oncology
https://doi.org/10.1016/j.ygyno.2006.12.021